The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma.

Tariq, Syed Maaz; Abdallah, Al-Ola; Goodman, Aaron; Sborov, Douglas; Mohyuddin, Ghulam Rehman; Britt, Alec.

Afiliação

Tariq SM; Jinnah Sindh Medical University, Karachi, Pakistan.
Abdallah AO; Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Goodman A; Division of Hematology and Oncology, University of California San Diego, La Jolla, CA, USA.
Sborov D; Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, UT, USA.
Mohyuddin GR; Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, UT, USA. g.mohyuddin@hci.utah.edu.
Britt A; Division of Hematological Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.

Clin Hematol Int ; 5(2-3): 170-176, 2023 Jun.

Article em En | MEDLINE | ID: mdl-37133718

ABSTRACT

Maintenance therapies in multiple myeloma improve survival after induction treatment. This study characterizes the strategies for maintenance therapy being employed in currently enrolling clinical trials for patients with multiple myeloma and highlights how high-risk myeloma patients may be assigned to maintenance strategies incongruent with current US guidelines.

Palavras-chave

Landscape; Lenalidomide; Maintenance; Myeloma

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article